Trial Group - Gastrointestinal

Bile duct cancer that is inoperable or has spread, in patients that test positive for FGFR2 gene fusion, or, FGFR2 gene mutations or amplifications.

To investigate the effects of the drug derazantinib (formerly ARQ 087) in patients who have a type of bile duct cancer that cannot be operated on, or has spread, called Advanced Intrahepatic Cholangiocarcinoma. Patients will have a positive genetic test for FGFR2 Gene Fusion or FGFR2 gene mutations or amplifications.

Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement

The purpose of this trial is to evaluate the efficacy of pemigatinib versus standard chemotherapy in the first-line treatment of patients with Unresectable or Metastatic Cholangiocarcinoma, whos tumors harbor FGFR2 gene rearrangement.

Advanced oesophago-gastric or colorectal cancer

The purpose of this trial is to determine the safety and efficacy of the drug lithium and the optimum dose when used with standard chemotherapy.

Hepatocellular Carcinoma

This study will evaluate the safety and efficacy of pembrolizumab (MK-3475) versus placebo as adjuvant therapy in participants with hepatocellular carcinoma (HCC) and complete radiological response after surgical resection or local ablation (KEYNOTE-937).

Metastatic colorectal cancer (bowel cancer) that is unresectable and not suitable for intensive therapy

The main purpose of the study is to determine if S95005 in combination with bevacizumab is better than capecitabine with bevacizumab for progression free survival in mCRC patients who have not received any treatment for metastatic disease yet and are not suitable for intensive chemotherapy

This study is for patients with hepatocellular cancer (type of liver cancer) which has spread (metastasised)

To compare the safety and efficacy between the two groups in this study – those treated with Lenvatinb and Pembrolizumab and those treated with Lenvatib alone.

Previously untreated HER2 negative advanced cancer of the stomach or the junction between the stomach and the oesophagus (gastrooesophageal junction).

This trial will compare the effectiveness of a drug called Pembrolizumab used in combination with chemotherapy, to a placebo used in combination with chemotherapy.

Patients will be randomly assigned (randomised) between either Pembrolizumab and chemotherapy, or placebo and chemotherapy.

Cancer of the oesophagus or gastro-oesophageal junction which has spread (metastasised).

To compare survival between the two groups – those treated with Trastuzumab, chemotherapy and Pembrolizumab and those treated with Trastuzumab, chemotherapy and placebo.

Patients with cancer of the colon which has spread (metastasised).

The aim of the study is to identify and confirm one or more biomarkers (a biological substance) in blood and/or tissue, which will help us to identify the patients, who are going to respond to their treatment.

Cancer of the rectum.

The purpose of this trial is to compare two radiotherapy techniques for treating locally advanced rectal cancer.